Skip to main content
  1. Right Decisions
  2. GGC - Clinical Guidelines
  3. Gynaecology
  4. Back
  5. Gynaecology guidelines
  6. Elevated CA125: investigation & management, Gynaecology (1113)
Please update your RDS mobile app to version 4.7.1

We are pleased to advise that deep linking capability, enabling users to directly download individual mobile toolkits, has now been released on the RDS mobile app. When you install the update, you will see that each toolkit has a small QR code icon the header area beside the search icon – see screenshot below. Clicking on this icon will open up a window with a full-size QR code and the alternative of a short URL for sharing with users. Instructions are provided.

You may need to actively install the update to install RDS app version 4.7.1 to see this improvement. Installing this update is also strongly recommended to get the full benefits of the new contingency arrangements – specifically, that if the RDS website should fail, you will still be able to download new mobile app toolkits. 

To check your current RDS version, click on the three dots bottom right of the RDS app screen. This takes you to a “More” page where you will see the version number.  To install latest updates:

On iPhones – go to the Apple store, click on your profile icon top right, scroll down to see the apps waiting to be updated and update the RDS app.

On Android phones – these can vary, but try going to the Google Play store, click on your profile icon top right, click on “Manage apps and device”, select and update the RDS app.

Please get in touch with ann.wales3@nhs.scot with any questions.

Elevated CA125: investigation & management, Gynaecology (1113)

Warning

Objectives

To provide guidance on how to investigate women where a raised CA125 is found

Audience

Healthcare providers in primary and secondary care in Great Glasgow and Clyde (GGC)

CA125 is considered to be the best available marker for epithelial ovarian cancer.  

The widely accepted normal range of CA125 in GGC is 0-35 IU/ml.

Clinical Specificity of CA125

CA125 may be elevated in many physiological and pathological conditions, with gynaecological and non-gynaecological causes.  These conditions are summarised in the table below.

Table: list of conditions causing a raised CA125

CA125 Testing Recommendations

Primary Care

NICE recommends CA125 testing in primary care in women presenting with  1 of these following symptoms on a persistent or frequent basis, particularly if ≥ 12 x per month.

  • Persistent abdominal distension (‘bloating’)
  • Early satiety +/- loss of appetite
  • Pelvic or abdominal pain
  • Increased urinary urgency +/- frequency
  • Unexplained weight loss
  • Unexplained fatigue
  • Unexplained change of bowel habit
  • New onset of symptoms suggestive of IBS if 50 years

If CA125 is elevated >35 IU/ml, arrange an Ultrasound of the Pelvis – ideally Transvaginal Scan within 2 weeks.

Additionally if physical examination in primary care suggests ascites and or a pelvic or abdominal mass (which is not obviously uterine fibroids) they should be referred urgently for review in gynaecology and referral should not be delayed whilst waiting for CA125 result. 

Secondary Care

Abnormal Ultrasound Scan or imaging findings – premenopausal women

The Royal College of Obstetricians and Gynaecologists (RCOG) advises that a CA125 level is not routinely needed for the diagnosis of a simple cysts in premenopausal women. 

If germ cell origin tumours are suspected following imaging (e.g. women < 40yrs), αFP, βHCG and LDH are recommended in addition to CA125.

Please see GGC guidelines for further details.

Abnormal Ultrasound Scan or imaging findings – postmenopausal women

A CA125 level should be measured in all postmenopausal women with a cystic lesion of 1cm or more.  This should be used in conjunction with the USS findings to calculate the Risk of Malignancy Index Score (RMI).  Please see GGC guidelines for further details.

Normal pelvic ultrasound scan or imaging & Raised CA125

If a CA125 has been measured prior to imaging, a normal ultrasound can exclude ovarian cancer with a high degree of confidence. 

Postmenopausal ovaries will appear smaller and more homogenous compared to those found in pre-menopausal women. It is therefore common not to visualize the ovaries on ultrasound in a postmenopausal woman.  For completeness an abdominal examination and bimanual examination may be undertaken to assess for potential non pelvic masses.

In the presence of a normal pelvic ultrasound scan or imaging, there is no clear evidence to repeat a CA125 measurement.  However, extrapolating from ovarian cyst data, a rapidly rising CA125 is more likely to be associated with malignancy, therefore consider a repeat CA125 after 8 weeks to assess trend.  If significantly rising, further imaging by urgent CT scan of abdomen and pelvis should be arranged. 

If no gynaecological cause identified, patient should be referred back to GP to assess for other clinical causes of symptoms and investigate or refer as appropriate.

CA125 Flowchart

Flowchart of the steps for elevated CA125 investigations

Editorial Information

Last reviewed: 14/11/2023

Next review date: 31/10/2027

Author(s): Dr Jenifer Sassarini, Consultant O&G; Dr Claire Higgins Consultant O&G.

Approved By: Gynaecology Clinical Governance Group

Document Id: 1113

References

Ovarian cancer: recognition and initial management. NICE Guideline CG122 April 2011, Last review 2017.

Suspected cancer: recognition and referral, NICE guideline [NG12] Published: June 2015 Last updated: December 2021

Howe T, Sokolovsky N, Sayasneh A, Omar K, Tahmasebi F. Raised CA125–what we actually know... The Obstetrician & Gynaecologist2021;23:21–7.

RCOG Green-top Guideline No. 62. Management of suspected ovarian masses in premenopausal women. Dec 2011.

RCOG Green-top Guideline No. 34. Ovarian cysts in postmenopausal women. July 2016.

ACOG Practice Bulletin No. 174: Evaluation and Management of Adnexal Masses, Obstetrics & Gynecology: November 2016 - Volume 128 - Issue 5 - p e210-e226

ACOG COMMITTEE OPINION Number 716 , September (Reaffirmed 2019) Committee on Gynecologic Practice Society of Gynecologic Oncology. The Role of the Obstetrician–Gynecologist in the Early Detection of Epithelial Ovarian Cancer in Women at Average Risk